Zhendong Chen

Feb 1, 2024 | nature.com | Jin Billy Li |Zhendong Chen

AbstractAlthough antiprogrammed death 1 antibody plus chemotherapy has recently been approved for first-line esophageal squamous cell carcinoma (ESCC), antiprogrammed death-ligand 1 antibody may offer another combination option in this setting. In this multicenter, randomized, double-blinded phase 3 trial a total of 540 adults (aged 18–75 years) with unresectable, locally advanced, recurrent or metastatic ESCC and who had not received systemic treatment were enrolled.

Dec 28, 2023 | onlinelibrary.wiley.com | Pei Lin |Zhendong Chen |Jun Lin

Gout is a chronic, inflammatory, and metabolic disease caused by the deposition of monosodium urate (MSU) crystals.

Nov 10, 2023 | bmccancer.biomedcentral.com | Yu Yang |Zhendong Chen

We retrospectively analyzed data from 149 GC patients who were treated with PD-1 inhibitors, excluding 30 patients who were lost to follow-up. Patients’ clinicopathological characteristics at the initiation of anti-PD-1 therapy, both of all patients (n = 149) and separated by serum iron status, are listed in Table 1. There was a male preponderance (n = 113; 75.8%) with a male-to-female ratio of 3.14:1.